Fig. 3

Clinical value and prognostic role of tRF-23-Q99P9P9NDD in GC serum. A The expression levels of tRF-23-Q99P9P9NDD in serum samples from GC patients (n = 124), gastritis patients (n = 50), and healthy donors (n = 119). B The expression level of tRF-23-Q99P9P9NDD in different stages of the depth of tumor invasion and healthy donors (T1–T2: n = 69, T3–T4: n = 55, healthy donors: n = 119). C The expression levels of tRF-23-Q99P9P9NDD in serum of GC patients with (n = 76) or without lymph node metastasis (n = 48). D The expression levels of tRF-23-Q99P9P9NDD in serum of stage I–II GC patients (n = 82), stage III–IV patients (n = 42), and healthy donors (n = 119). E The expression level of tRF-23-Q99P9P9NDD in serum of GC patients with (n = 78) or without nerve/vascular invasion (n = 46). F Changes in the serum expression levels of tRF-23-Q99P9P9NDD in 40 GC patients before and after surgery. G Differences in the expression levels of tRF-23-Q99P9P9NDD in the postoperative serum of GC patients and healthy donors. H Kaplan–Meier curve analysis of the relationship between the expression levels of tRF-23-Q99P9P9NDD and the survival of GC patients. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001